Trinity Biotech (TRIB) Total Non-Current Liabilities (2009 - 2025)

Trinity Biotech's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $35.9 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 66.22% year-over-year to $35.9 million; the TTM figure through Dec 2025 stood at $35.9 million (down 66.22% YoY), while the FY2025 annual figure was $35.9 million, down 66.22% from the prior year.
• Total Non-Current Liabilities came in at $35.9 million for Q4 2025 at Trinity Biotech, down from $117.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $117.6 million in Q2 2025 to a low of $18.7 million in Q4 2021.
• A 5-year average of $73.3 million and a median of $77.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 82.26% in 2021 and soared 310.94% in 2022, its largest moves.
• Trinity Biotech's Total Non-Current Liabilities stood at $18.7 million in 2021, then surged by 310.94% to $76.9 million in 2022, then fell by 11.17% to $68.3 million in 2023, then jumped by 55.64% to $106.4 million in 2024, then slumped by 66.22% to $35.9 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $35.9 million, $117.6 million, and $106.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison